Bridger Management LLC Sells 17,214 Shares of Novo Nordisk A/S $NVO

Bridger Management LLC lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 14.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 104,386 shares of the company’s stock after selling 17,214 shares during the period. Novo Nordisk A/S makes up approximately 4.2% of Bridger Management LLC’s holdings, making the stock its 10th largest position. Bridger Management LLC’s holdings in Novo Nordisk A/S were worth $7,205,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Stone House Investment Management LLC acquired a new position in shares of Novo Nordisk A/S during the first quarter worth approximately $30,000. NewSquare Capital LLC increased its position in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares during the period. Disciplina Capital Management LLC raised its stake in Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 297 shares during the last quarter. Dagco Inc. bought a new stake in Novo Nordisk A/S in the 1st quarter valued at $35,000. Finally, Mid American Wealth Advisory Group Inc. bought a new stake in Novo Nordisk A/S in the 2nd quarter valued at $37,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.5%

NVO stock opened at $48.52 on Tuesday. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $112.52. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The business’s 50 day moving average is $54.44 and its 200-day moving average is $60.85. The firm has a market cap of $216.63 billion, a P/E ratio of 13.33, a P/E/G ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.74 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on NVO shares. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. BNP Paribas Exane upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price objective for the company in a research report on Wednesday, August 13th. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Finally, Jefferies Financial Group assumed coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.